Beginner view — everything explained simply.
The detailed substance texts are currently available in German only. The interface and navigation are translated; the specialist content will follow in reviewed quality.
Research updates
Dated snapshots of the research landscape: we clearly separate approved, clinically tested compounds from popular but unproven “wellness” peptides. Each post documents the state of evidence on its publication date and is backed by primary sources — with no dosing or usage information.
Peptide-World Update, Autumn 2026: Approvals, Phase 3 Data and the First BPC-157 Trial Start
What has moved since summer 2026: a new cardiovascular approval for tirzepatide (but not in the EU), the oral Wegovy tablet now in Europe too, peer-reviewed Phase 3 data on retatrutide and survodutide – and, for the 'wellness' peptides, tougher regulators plus the very first registered BPC-157 human trial.
Read morePeptide Research 2024–2026: What the Studies Actually Show
A sober overview of the latest peptide research: where the approved incretin class convinces with hard Phase 3 data, where even Semaglutide fails – and why "wellness" peptides such as BPC-157 or Epitalon still stand without any controlled human trials.
Read more